Lung cancer is still one of the most common malignancies with a high global mortality rate with over 2 million cases confirmed by the World Health Organization in 2018. Although there has been ...
A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer. Precise ...
From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.
Broad enrollment criteria appear to have scuttled the trial, which was designed to test whether ctDNA could identify patients ...
PRNewswire/ -- iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today provides a clinical update on ...
Financially, Immunocore has a strong cash position and stable revenue growth, but concerns remain about the pipeline's ...
By inferring proliferation rates from single-cell genomics, SPRINTER enhances understanding of tumor evolution and identifies ...
The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed by Cancer Research UK-funded scientists from UCL and The Francis Crick ...
The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed ...
This was her body’s reaction to the cancer cells, which had spread from her right lung, where the tumour originated, to her left lung, affecting her spine and lymph nodes. “I couldn’t walk ...
The phase 3 SKYSCRAPER-01 trial of tiragolumab and atezolizumab in PD-L1-high non–small cell lung cancer did not meet its primary end point of overall survival. The primary end point of overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback